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Abstract
Background: Efavirenz is the preferred non-nucleoside reverse transcriptase inhibitor for first-line antiretroviral treatment in
many countries. For women of childbearing potential, advantages of efavirenz are balanced by concerns that it is teratogenic.
This paper reviews evidence of efavirenz teratogenicity and considers implications in common clinical scenarios.
Findings: Concerns of efavirenz-induced fetal effects stem from animal studies, although the predictive value of animal data for
humans is unknown. Four retrospective cases of central nervous system birth defects in infants with first trimester exposure to
efavirenz have been interpreted as being consistent with animal data. In a prospective pregnancy registry, which is subject to
fewer potential biases, no increase was detected in overall risk of birth defects following exposure to efavirenz in the first-
trimester.
Discussion: For women planning a pregnancy or not using contraception, efavirenz should be avoided if alternatives are
available. According to WHO guidelines for resource-constrained settings, benefits of efavirenz are likely to outweigh risks for
women using contraception. Women who become pregnant while receiving efavirenz often consider drug substitution or
temporarily suspending treatment. Both options have substantial risks for maternal and fetal health which, we argue, appear
unjustified after the critical period of organogenesis (3–8 weeks post-conception). Efavirenz-based triple regimens, initiated after
the first trimester of pregnancy and discontinued after childbirth, are potentially an important alternative for reducing mother-
to-child transmission in pregnant women who do not yet require antiretroviral treatment.
Conclusion: Current recommendations for care for women who become pregnant while receiving efavirenz may need to be
re-considered, particularly in settings with limited alternative drugs and laboratory monitoring. With current data limitations,
additional adequately powered prospective studies are needed.
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Background
An increasing number of women worldwide are benefit-
ing from expanding access to antiretroviral treatment,
allaying initial concerns that women would have inequi-
table access to treatment. In sub-Saharan Africa nearly six
out of ten adults receiving antiretroviral (ARV) treatment
are women, an equitable distribution as more women are
infected than men [1]. A substantial proportion of these
women will plan to conceive or have unintended preg-
nancies [2]. This raises concerns of potential ARV-induced
fetal effects. Such concerns often require women and their
clinicians to make trade-offs between reproductive and
treatment choices.
Efavirenz (EFV) is the preferred non-nucleoside reverse
transcriptase inhibitor (NNRTI) in many countries [3-5]
as it is less hepatotoxic than nevirapine (NVP), does not
require dose adjustment and can be used concomitantly
with tuberculosis treatment. However, for women of
reproductive potential these advantages are balanced by
concerns that EFV increases risk for birth defects.
This paper reviews evidence of EFV teratogenicity and con-
siders implications for common clinical scenarios.
Evidence of efavirenz teratogenesis
Pregnant women are actively excluded from clinical trials
during drug development. Assessment of drug safety in
pregnancy is therefore based on less rigorous evidence,
such as reproductive toxicology studies in small mammals
and non-human primates, retrospective case reports and
pregnancy registry data.
Concerns of EFV-induced fetal effects began after a trial
with cynomolgus monkeys [6]. In the trial, monkeys were
exposed to EFV throughout pregnancy at plasma drug
concentrations similar to humans receiving 600 mg EFV
per day. No major congenital malformations were
observed in 20 control infant monkeys, but 3 of 20 EFV-
exposed infants had significant abnormalities [6]. Anen-
cephaly and unilateral anophthalmia were observed in
one monkey infant, microphthalmia in another and cleft
palate in a third. An increase in fetal resorptions was
observed in rats given EFV, but no significant teratologic
findings were reported in studies with pregnant rabbits
treated with EFV [7]. Thus far in humans, four retrospec-
tive cases of central nervous system (CNS) defects in
infants with first trimester exposure to EFV have been
reported (three infants with meningomyelocele and one
with a Dandy-Walker malformation) [7-9].
The predictive value of animal studies for humans is
unknown; making it difficult for health workers to trans-
late animal risks into an assessment of teratogenic risk in
their patients. Many associations have ultimately been
shown to be false positive in humans and in some
instances drug testing in animals has been negative and
the drug subsequently shown to be teratogenic in humans
[10]. Of approximately 1 200 animal teratogens, only
about 30 are known to be teratogenic in humans [11].
However, the EFV animal studies are particular concern-
ing as abnormalities were observed in primates at drug
levels comparable to therapeutic ranges in humans and
positive findings were detected in more than one animal
species.
The retrospective case reports in humans are difficult to
interpret as neural tube defects are among the commonest
birth defects (occurring in about 1 in 1000 pregnancies,
with marked ethnic and geographic variation in preva-
lence [12]). A few case reports can establish a strong asso-
ciation if a drug is taken by a relatively small number of
women, causes a characteristic or obvious pattern of
abnormalities (as is the case with most teratogens, for
example thalidomide, warfarin and retinoic acid), or
results in a rare malformation [13]. However, reports of
common defects may reflect either background occur-
rence of these malformations in the general population or
an increased risk for drug-induced birth defects. Moreo-
ver, without knowing the denominator (the total number
of infants exposed to EFV in the first trimester of preg-
nancy), the relative risk of exposure is unknown.
Studies with prospectively followed pregnancies are sub-
ject to fewer biases than retrospective case reports. Enrol-
ment in these studies occurs before the outcome of
pregnancy is known and prior to tests that could provide
knowledge of pregnancy outcome, such as antenatal ultra-
sound or alpha-fetoprotein measurement. These studies
have been used to support a change in the United States
Federal Drug Administration (FDA) pregnancy risk cate-
gory, for example acyclovir changed to category B: "Posi-
tive animal data but adequate and well-controlled studies
in humans failed to show a fetal risk".
In an prospective antiretroviral pregnancy registry based
in the United States, birth defects were observed in 5 of
228 (2.2%; 95% CI: 0.7%-5.1%) live-born infants follow-
ing first-trimester exposure to EFV and in 1 of 14 live
births with second- or third-trimester exposure [14]. This
prevalence of birth defects is comparable to the United
States general population (3.1%; 95% CI: 3.1%-3.2%)
[15]. The European Collaborative Study also collects data
on pregnancy outcomes following ARV exposure during
pregnancy. Thus far, 19 women in this study have become
pregnant while receiving EFV-containing regimens, no
congenital abnormalities were reported (0%; 95% CI: 0%-
17.6%) [16]. In contrast to findings of the United States
registry and European Collaborative Study, in a French
cohort three of ten infants born to women who becameAIDS Research and Therapy 2006, 3:11 http://www.aidsrestherapy.com/content/3/1/11
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pregnant while receiving EFV had birth anomalies [17].
None of the prospectively reported anomalies in the
United States antiretroviral pregnancy registry or the
French cohort were similar to those in the animal study or
case reports.
A sufficient number of live births have been monitored in
the United States antiretroviral pregnancy registry to
detect a two-fold increase in overall risk for birth defects
following first-trimester exposure to EFV; no such increase
has been detected [14,18]. Several features of the registry
limit the ability to draw definitive conclusions. Of eligible
woman-infant pairs, only about 15% are enrolled [14]. It
is unknown whether those not enrolled are at higher or
lower risk of birth defects. Moreover, ascertainment of
birth defects is not standardised, with varying use of diag-
nostic tests and level of expertise of reporting clinicians.
Nevertheless, this evidence does provide some assurance
that EFV is not a major human teratogen [19]. In sum,
these findings indicate that any overall increase in risk for
birth defects following exposure to EFV is likely to be low.
However, larger studies are required to exclude an
increased risk for specific congenital anomalies such as
neural tube defects; current prospective studies have inad-
equate power to draw conclusions about the risk of neural
tube defects [19].
Efavirenz use in women of childbearing potential
In the FDA classification EFV is a category D drug: "Posi-
tive evidence of human fetal risk. Nevertheless, potential
benefits may outweigh the potential risks" [20]. This dis-
claimer is understandable from a medicolegal standpoint,
but provides no practical information for deciding
whether potential benefits to a woman outweigh risks to
a fetus or how to respond to inadvertent fetal exposures
[21]. Furthermore, several critics argue that drugs are com-
monly assigned high-risk FDA categories based on limited
information [13,21].
Two commonly used ARV treatment guidelines, devel-
oped by WHO and the United States Public Health Service
Task Force, both recommend that EFV be avoided among
women trying to conceive or not using contraception
[22,23]. However, they differ for women using contracep-
tion. WHO guidelines indicate that EFV is a viable option
for women using effective contraception [23], whereas
guidelines from the United States recommend alternatives
to EFV should be strongly considered because of known
failure rates of contraception [22]. These guidelines target
different settings with considerable variation in availabil-
ity of ARV treatment options, which may account for dif-
fering recommendations.
Based on advantages of EFV and that existing data indi-
cates any increase in overall risk for birth defects is likely
to be small, withholding EFV-based treatment from
women using contraception in settings with limited ARV
options is likely to cause more harm than its provision.
Further, safety advantages of EFV are particularly impor-
tant in many high HIV burden settings with limited capac-
ity for clinical and laboratory monitoring.
Withholding such treatment is contrary to principles guid-
ing use of other drugs essential for a woman's health such
as antiepileptic medication [24,25]. Much evidence indi-
cates that carbamazepine and sodium valproate increase
risk for neural tube defects [26,27], but in view of the need
for effective control of seizures, recommendations are that
in almost all cases, the optimum drug for controlling sei-
zures should be used [24,25]. Principles guiding care for
women with epilepsy share commonalities with those
guiding ARV treatment decisions and could assist policy
makers in selecting ARV regimens for women. This com-
parison applies particularly in settings with limited alter-
native drugs, while is less relevant to high-income
countries with increased ARV options.
Analogous to antiepileptic medication, benefits of ARV
treatment accrue both to the woman and to her fetus, and
are likely to outweigh potential harm to the fetus. ARV
treatment for women reduces mortality and morbidity, is
the most effective method of preventing HIV transmission
to the infant, and by securing the health of women,
improves child survival [23,28]. On the basis of available
evidence, several authors argue that decisions to initiate
ARV treatment should be based primarily on a woman's
need for such treatment [23,29,30].
Risk of unintended pregnancy is low with correct and con-
sistent use of contraception [31]. However, evidence that
EFV increases bioavailability of steroid hormones in hor-
monal contraceptives must be considered when selecting
a contraceptive method [32]. Increased bioavailability
may increase risk for estrogen- or progestin-related side
effects. Alternative contraceptive methods with low typi-
cal-use failure rates need to be considered [31].
Women receiving EFV-containing regimens may later plan
to become pregnant or have an unintended pregnancy
[33]. For women who plan conception, substitution with
NVP or a PI needs to be considered, although risks and
benefits of substitution should be taken into account (Box
1). Drug substitution is best undertaken prior to preg-
nancy.
Some studies suggest teratogenic activity of drugs that
increase risk for neural tube defects is mediated by inter-
ference with folic acid metabolism and that folic acid sup-
plementation protects against teratogenic effects of these
drugs [34,35]. Although potential mechanisms of EFV-AIDS Research and Therapy 2006, 3:11 http://www.aidsrestherapy.com/content/3/1/11
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induced fetal effects are unknown, folic acid supplemen-
tation is important for women receiving EFV as it is for
other women of childbearing age.
Use of efavirenz during pregnancy
Pregnancy recognition often occurs after the critical
period of organogenesis (3–8 weeks post-conception).
Development and closure of the neural tube are normally
complete by 28 days post-conception, approximately the
same gestation when the first symptoms of pregnancy
occur. Changes to EFV-based regimens after four weeks
post-conception will not reduce the risk of neural tube
defects and after eight weeks will have minimal effect on
risk for other structural malformations. There are theoret-
ical risks that exposure to EFV or other ARV drugs in the
second and third trimester of pregnancy could affect neu-
rodevelopment of infants. However, in the absence of evi-
dence from neurobehavioral development studies, effects
of exposure to any ARV drug after the period of organo-
genesis remain speculative.
Women who realise they are pregnant early in gestation
can consider substituting EFV with NVP or a PI, or tempo-
rarily suspending treatment. Substituting EFV with
another ARV drug is commonly considered, but is not
without risk [23] (Box 1).
Box 1. Factors to consider when substituting efavirenz in
pregnant women:
• Following substitution, women have to get used to a
new ARV regimen, with different side-effects, pill counts
and dosing times;
• Treatment-related increases in CD4 cell count may have
occurred. Substituting EFV with NVP in women with treat-
ment-related CD4 cell restoration to levels above 250
cells/mm3 could, in theory, place them at increased risk
for NVP-associated hepatotoxicity;
• In many settings alternative ARV drugs are limited by
availability, cost or co-existing conditions; and
• Substituting EFV with other drugs may limit the effec-
tiveness of future regimens. Pharmacokinetic evidence
suggests that when substituting EFV with NVP, women
should commence on 200 mg twice a day, as dose escala-
tion of NVP is associated with sub-therapeutic NVP levels
in these individuals [36].
Temporarily suspending ARV treatment also has several
risks. Suspending ARV treatment at recognition of preg-
nancy has been associated with significant viral rebound
and CD4 cell count decline [37], potentially increasing
risk for HIV transmission to the fetus and compromising
a woman's health. In addition, EFV has a longer half-life
than nucleoside analogue reverse transcriptase inhibitor
(NRTI) drugs resulting in functional monotherapy, which
increases risk for viral resistance [38,39]. Many experts rec-
ommend continuing the NRTI backbone for a period of
time after NNRTI discontinuation [5,22]. Although evi-
dence is accumulating [40,41], the optimal interval
between stopping NNRTI and other ARV drugs is
unknown.
Women who become pregnant while receiving EFV
require counselling and full information on potential
risks to the fetus. High-quality counselling entails non-
directive individualised discussion of options and support
for a woman to make an autonomous decision about use
of ARV drugs or termination of pregnancy, to the extent
allowed by law [42]. It is important to note that an exag-
gerated perception of fetal risk can result in a woman ter-
minating an otherwise wanted pregnancy [13]. Such
decisions are complex and underpinned by biomedical as
well as socio-cultural considerations.
Women who become pregnant while receiving EFV may
benefit from screening for CNS abnormalities with a fetal
anomaly ultrasound or maternal serum alpha-fetoprotein
test [43]. These non-invasive tests are preferable as amni-
ocentesis has been associated with increased risk for HIV
infection in infants [44].
Efavirenz for preventing HIV infection in infants
Advocacy is mounting for prevention of mother-to-child
transmission (MTCT) programmes in resource-con-
strained settings to introduce more effective ARV prophy-
laxis than single-dose (maternal and infant) NVP [45,46].
Evidence is accumulating of the feasibility of providing
triple-ARV regimens for prophylaxis in resource-con-
strained settings [47,48]. In Brazil, Europe and the United
States, for a woman without indications for ARV treat-
ment, triple-ARV prophylaxis is provided during preg-
nancy and discontinued after childbirth [22,49,50], and
the risk of transmitting HIV to her infant is less than 2%
[51,52]. Triple-ARV prophylaxis is used for almost all
pregnant women with HIV in these settings. For example,
United States MTCT-prevention guidelines state: "Stand-
ard combination antiretroviral regimens for treatment of
HIV-1 infection should be discussed and offered to all
pregnant women with HIV-1 infection regardless of viral
load; they are recommended for all pregnant women with
HIV-1 RNA levels greater than 1000 copies/mL" [22].
MTCT-prophylaxis regimens are initiated after the first tri-
mester of pregnancy, hence past the period of organogen-
esis. An EFV-containing triple ARV regimen could be a
useful alternative for MTCT-prevention programmes that
adopt similar strategies to Brazil, the United States andAIDS Research and Therapy 2006, 3:11 http://www.aidsrestherapy.com/content/3/1/11
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Europe. Based on WHO guidelines, EFV-based triple regi-
mens are a viable option for MTCT prophylaxis [23].
Alternative triple regimens for pregnant women without
indications for ARV treatment pose several difficulties:
women with a high CD4 cell count have an increased risk
for hepatotoxicity with NVP; and protease inhibitor con-
taining regimens have a higher pill burden, more complex
side-effect profile and higher cost.
Conclusion
Existing ARV treatment guidelines do not adequately
address the complex clinical scenarios that women and
clinicians increasingly face. This has compounded diffi-
culties in making the inevitable trade-offs between repro-
ductive and treatment choices. Based on existing evidence
we have outlined general considerations in these scenar-
ios. In particular, as described in current WHO guidelines
for resource-constrained settings, the benefits of EFV are
likely to outweigh risks for women using contraception.
However, we argue that in women who become pregnant
while receiving EFV, a decision to temporarily suspend
treatment or to substitute EFV after the period of organo-
genesis is unwarranted, especially in settings with limited
alternative drugs. Moreover, given limitations of existing
data, additional evidence is needed to assist individual
patients to balance risks and benefits.
Several research centres in Africa have the capacity to
recruit an adequate number of exposed woman-infant
pairs and to ensure high rates of cohort retention and
accurate ascertainment of pregnancy outcomes. With the
rapid increase in women receiving ARV treatment in Africa
and as EFV is the preferred NNRTI in many settings, these
centres are ideally situated to establish an adequately
powered ARV registry. Additional scientifically valid data
and estimates of relative risk would provide more detailed
information of potential risks, or conversely offer further
reassurance that EFV and other ARV drugs are not major
human teratogens. Without this evidence, creating policy
consensus is difficult and women will continue to face
reproductive decisions with limited information.
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